1246303-14-9

1246303-14-9 structure

Name: VU0359595
Chemical Name: (1R,2R)-N-{(2S)-1-[4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]-2-propanyl}-2-phenylcyclopropanecarboxamide
CAS Number: 1246303-14-9
Molecular Formula: C₂₅H₂₉BrN₄O₂
Molecular Weight: 497.427
Catalog: Signaling Pathways Metabolic Enzyme/Protease Phospholipase
Create Date: 2018-04-17 16:02:55
Modify Date: 2025-08-25 13:33:44
VU0359595 (CID-53361951; ML-270) is a potent and selective pharmacological phospholipase D1 (PLD1) inhibitor with an IC50 of 3.7 nM. VU0359595 is >1700-fold selective for PLD1 over PLD2 (IC50 of 6.4 μM). VU0359595 can be used for the research of cancer, diabetes, neurodegenerative and inflammatory diseases[1][2][3][4].

Name	(1R,2R)-N-{(2S)-1-[4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]-2-propanyl}-2-phenylcyclopropanecarboxamide
Synonyms	Cyclopropanecarboxamide, N-[(1S)-2-[4-(5-bromo-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-methylethyl]-2-phenyl-, (1R,2R)- (1R,2R)-N-{(2S)-1-[4-(5-Bromo-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]-2-propanyl}-2-phenylcyclopropanecarboxamide

Description	VU0359595 (CID-53361951; ML-270) is a potent and selective pharmacological phospholipase D1 (PLD1) inhibitor with an IC50 of 3.7 nM. VU0359595 is >1700-fold selective for PLD1 over PLD2 (IC50 of 6.4 μM). VU0359595 can be used for the research of cancer, diabetes, neurodegenerative and inflammatory diseases[1][2][3][4].
Related Catalog	Research Areas >> Cancer Research Areas >> Infection Signaling Pathways >> Metabolic Enzyme/Protease >> Phospholipase Research Areas >> Inflammation/Immunology Research Areas >> Metabolic Disease Research Areas >> Neurological Disease
Target	PLD1:3.7 nM (IC50) PLD2:6.4 μM (IC50)
In Vitro	VU0359595 (5, 50, 500, 5000 nM) inhibits basal and FCS/IGF-1 stimulated proliferation of astroglial cells[2] . VU0359595 (5, 50, 500 nM; 30 min) does not affect basal PLD activity in astrocytes but reduces mitogen-stimulated PLD activity in a concentration-dependent manner[2]. VU0359595 (0.15 μM; 1 h before high glucose treatment and 4 h during high glucose treatment) partially reduces the increase [3H]-phosphatidylethanol (PEth) generation induced by high glucose (33 mM) in retinal pigment epithelium (RPE) cells[3]. VU0359595 (5 μM; 1 h prior to LPS treatment) modulates the autophagic process of LPS-induced (10 μg/ml; 24 h) RPE cells[4].
References	[1]. Lewis JA, et al. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity. Bioorg Med Chem Lett. 2009;19(7):1916-1920. [2]. Burkhardt U, et al. Phospholipase D is a target for inhibition of astroglial proliferation by ethanol. Neuropharmacology. 2014;79:1-9. [3]. Tenconi PE, et al. High glucose-induced phospholipase D activity in retinal pigment epithelium cells: New insights into the molecular mechanisms of diabetic retinopathy. Exp Eye Res. 2019;184:243-257. [4]. Bermúdez V, et al. Lipopolysaccharide-Induced Autophagy Mediates Retinal Pigment Epithelium Cells Survival. Modulation by the Phospholipase D Pathway. Front Cell Neurosci. 2019;13:154. Published 2019 Apr 24.

Density	1.4±0.1 g/cm3
Molecular Formula	C₂₅H₂₉BrN₄O₂
Molecular Weight	497.427
Exact Mass	496.147369
LogP	4.71
Index of Refraction	1.631

RIDADR	NONH for all modes of transport

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

2228967-00-6	2228285-71-8
2229436-74-0	2229438-02-0
2229345-20-2	2229438-97-3
2229331-81-9	2227724-32-3
2229332-51-6	2229637-37-8